Stocks · News reference
Neurocrine Biosciences Announces Participation in 2026 Jefferies Global Healthcare Conference
Neurocrine Biosciences, Inc. announced that its executives will participate in the 2026 Jefferies Global Healthcare Conference in London on November 17, 2026.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Morgan Stanley Adjusts Neurocrine Biosciences Price Target
Morgan Stanley analyst Sean Laaman maintained a 'Neutral' rating on Neurocrine Biosciences while increasing the price target from $185 to $191.
GLP-1 RAs & Incretin-based Therapies Competitive Landscape Analysis: Key Developments by 200+ Companies Shaping the Treatment Landscape | DelveInsight
DelveInsight released a comprehensive competitive landscape report on GLP-1 receptor agonists and incretin-based therapies, covering 200+ pipeline drugs from 180+ active players. The report highlights approved drugs like MOUNJARO (tirzepatide) and OZEMPIC (semaglutide), with 30+ therapies in late-stage development and 60+ in mid/early stages. Key indications include obesity, type 2 diabetes, and cardiovascular outcomes. Recent developments include positive Phase III results for retatrutide, survodutide, and other dual/triple agonists from major pharmaceutical companies.
Neurocrine Biosciences Announces New Survey Results for INGREZZA
Neurocrine Biosciences released findings from a new survey indicating that adults with tardive dyskinesia report fewer work and school disruptions when treated with INGREZZA.
Analyst Price Target for Neurocrine Biosciences Increased
An analyst firm has raised the 12-month price target for Neurocrine Biosciences, Inc. to $209.27, indicating a potential upside of 44%.
Analysts Adjust Price Targets for Neurocrine Biosciences
Following the company's third-quarter 2026 financial results, RBC Capital Markets and Deutsche Bank have updated their price targets for Neurocrine Biosciences.